Did You Know...
...that after Walter Hunt patented the safety pin in 1849, he sold the rights to it for $400?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8137672 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which... | 03/20/2012 |
| 8088382 | Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates ... | 01/03/2012 |
| 8088383 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 01/03/2012 |
| 8080249 | Methods to treating chronic obstructive pulmonary disease The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, C... | 12/20/2011 |
| 7993648 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which... | 08/09/2011 |
| 7837997 | Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers. ... | 11/23/2010 |
| 7824684 | Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties ca... | 11/02/2010 |
| 7824683 | Methods for augmenting an immune response using anti-CD40 antibodies The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiate... | 11/02/2010 |
| 7820170 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 10/26/2010 |
| 7811570 | Method of affecting a function of or ablating a non-malignant cell Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or... | 10/12/2010 |
| 7763251 | Kits to assess the risk of tumor progression The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a ... | 07/27/2010 |
| 7731966 | Monoclonal antibodies against βintegrins Monoclonal antibodies prepared against platelet β3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using β3 integrin deficient (β3−/... | 06/08/2010 |
| 7700102 | Nucleic acids encoding CD100 molecules Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules ha... | 04/20/2010 |
| 7666422 | Methods for the treatment of cancer using anti-CD40 antibodies The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiate... | 02/23/2010 |
| 7666421 | Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2 The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant r... | 02/23/2010 |
| 7618633 | Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 11/17/2009 |
| 7611708 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 11/03/2009 |
| 7563442 | Antibodies to CD40 and methods of treating cancer and enhancing immune responses The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 07/21/2009 |
| 7563441 | Anti-P-selectin antibodies This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties ca... | 07/21/2009 |
| 7547438 | CD40-binding activating antibodies Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce ph... | 06/16/2009 |
| 7537763 | Anti-CD40 monoclonal antibody An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. ... | 05/26/2009 |
| 7531175 | Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune... | 05/12/2009 |
| 7510712 | Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 03/31/2009 |
| 7510711 | Methods for the treatment of cancer using anti-CD40 antibodies The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiate... | 03/31/2009 |
| 7510713 | Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 03/31/2009 |
| 7498032 | Methods for treating immune disorders or cancer with anti-CD40 antibodies The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiate... | 03/03/2009 |
| 7491393 | Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 02/17/2009 |
| 7445780 | Antagonistic anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 11/04/2008 |
| 7429647 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 09/30/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7422745 | Methods of treating cancer with αβ-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide ... | 09/09/2008 |
| 7422744 | Methods of treating cancer with alphavbeta3-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypepti... | 09/09/2008 |
| 7399471 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 07/15/2008 |
| 7393529 | Methods and compositions for inhibiting binding of IgE to a high affinity receptor The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals. ... | 07/01/2008 |
| 7371382 | Methods of inhibiting αβ-mediated binding with αβ-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αVβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Addit... | 05/13/2008 |
| 7361344 | Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of remova... | 04/22/2008 |
| 7361345 | Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the... | 04/22/2008 |
| 7354577 | Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to media... | 04/08/2008 |
| 7338660 | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 03/04/2008 |
| 7323170 | Anti-CD80 antibodies The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention... | 01/29/2008 |
